Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study
Abstract Background Acute coronary syndrome (ACS) remains the leading cause of death and disability worldwide, especially when combined with type 2 diabetes mellitus (T2DM). Many multicenter randomized controlled trials have established the cardiovascular benefits of Sodium-Glucose cotransporter 2 i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-023-03542-y |
| _version_ | 1797578240638844928 |
|---|---|
| author | Jie Chen Jing Chang Qiuyue Shi Xin Li Ling Wang Hong Zhao |
| author_facet | Jie Chen Jing Chang Qiuyue Shi Xin Li Ling Wang Hong Zhao |
| author_sort | Jie Chen |
| collection | DOAJ |
| description | Abstract Background Acute coronary syndrome (ACS) remains the leading cause of death and disability worldwide, especially when combined with type 2 diabetes mellitus (T2DM). Many multicenter randomized controlled trials have established the cardiovascular benefits of Sodium-Glucose cotransporter 2 inhibitors (SGLT-2i) in patients with T2DM at high cardiovascular risk. However, these studies did not include patients in the early stages of acute coronary events. This study investigated the cardiovascular protective effects of SGLT-2i in patients with ACS and T2DM. Methods A total of 232 hospitalized patients with ACS and T2DM were enrolled and divided into two groups based on their hypoglycemic drug treatment: the SGLT-2i and the non-SGLT-2i groups. Kaplan–Meier analysis and Cox regression were used to compare adverse cardiovascular outcomes in both groups. Results There were no significant differences in the hospital clinical outcomes between the SGLT-2i and non-SGLT-2i groups. The adverse cardiovascular outcomes did not significantly differ between both groups (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.35–1.25, P = 0.195). Moreover, the rehospitalization rates for ACS or heart failure (HF) were not significantly different between both groups (adjusted HR 0.56, 95%CI 0.28–1.10, P = 0.093). When analyzed separately, there was no significant difference in rehospitalizations for ACS (HR 0.87, 95% CI 0.40–1.87, P = 0.713). However, the SGLT-2i group showed lower rates of rehospitalizations for HF (adjusted HR 0.20, 95% CI 0.04–0.96, P = 0.045). Additionally, there was no significant difference in cardiovascular mortality between both groups (HR 1.75, 95% CI 0.28–10.97, P = 0.543). Notably, the SGLT-2i group exhibited a higher angina symptom control rate than the non-SGLT-2i group (adjusted odd ration (OR) 0.45, 95%CI 0.21–0.93, P = 0.031). Conclusion In recently diagnosed patients with ACS, who have T2DM, early initiation of SGLT-2i was associated with a lower risk of rehospitalization for HF and a higher rate of angina symptom control. |
| first_indexed | 2024-03-10T22:20:13Z |
| format | Article |
| id | doaj.art-46e5f9ec66bc4489b45074d5576c33b8 |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-03-10T22:20:13Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-46e5f9ec66bc4489b45074d5576c33b82023-11-19T12:18:28ZengBMCBMC Cardiovascular Disorders1471-22612023-10-0123111010.1186/s12872-023-03542-yCardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective studyJie Chen0Jing Chang1Qiuyue Shi2Xin Li3Ling Wang4Hong Zhao5Department of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityAbstract Background Acute coronary syndrome (ACS) remains the leading cause of death and disability worldwide, especially when combined with type 2 diabetes mellitus (T2DM). Many multicenter randomized controlled trials have established the cardiovascular benefits of Sodium-Glucose cotransporter 2 inhibitors (SGLT-2i) in patients with T2DM at high cardiovascular risk. However, these studies did not include patients in the early stages of acute coronary events. This study investigated the cardiovascular protective effects of SGLT-2i in patients with ACS and T2DM. Methods A total of 232 hospitalized patients with ACS and T2DM were enrolled and divided into two groups based on their hypoglycemic drug treatment: the SGLT-2i and the non-SGLT-2i groups. Kaplan–Meier analysis and Cox regression were used to compare adverse cardiovascular outcomes in both groups. Results There were no significant differences in the hospital clinical outcomes between the SGLT-2i and non-SGLT-2i groups. The adverse cardiovascular outcomes did not significantly differ between both groups (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.35–1.25, P = 0.195). Moreover, the rehospitalization rates for ACS or heart failure (HF) were not significantly different between both groups (adjusted HR 0.56, 95%CI 0.28–1.10, P = 0.093). When analyzed separately, there was no significant difference in rehospitalizations for ACS (HR 0.87, 95% CI 0.40–1.87, P = 0.713). However, the SGLT-2i group showed lower rates of rehospitalizations for HF (adjusted HR 0.20, 95% CI 0.04–0.96, P = 0.045). Additionally, there was no significant difference in cardiovascular mortality between both groups (HR 1.75, 95% CI 0.28–10.97, P = 0.543). Notably, the SGLT-2i group exhibited a higher angina symptom control rate than the non-SGLT-2i group (adjusted odd ration (OR) 0.45, 95%CI 0.21–0.93, P = 0.031). Conclusion In recently diagnosed patients with ACS, who have T2DM, early initiation of SGLT-2i was associated with a lower risk of rehospitalization for HF and a higher rate of angina symptom control.https://doi.org/10.1186/s12872-023-03542-ySodium-glucose cotransporter 2 inhibitorsAcute coronary syndromeType 2 diabetes mellitus |
| spellingShingle | Jie Chen Jing Chang Qiuyue Shi Xin Li Ling Wang Hong Zhao Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study BMC Cardiovascular Disorders Sodium-glucose cotransporter 2 inhibitors Acute coronary syndrome Type 2 diabetes mellitus |
| title | Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study |
| title_full | Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study |
| title_fullStr | Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study |
| title_full_unstemmed | Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study |
| title_short | Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study |
| title_sort | cardiovascular protective effect of sodium glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus a retrospective study |
| topic | Sodium-glucose cotransporter 2 inhibitors Acute coronary syndrome Type 2 diabetes mellitus |
| url | https://doi.org/10.1186/s12872-023-03542-y |
| work_keys_str_mv | AT jiechen cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy AT jingchang cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy AT qiuyueshi cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy AT xinli cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy AT lingwang cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy AT hongzhao cardiovascularprotectiveeffectofsodiumglucosecotransporter2inhibitorsonpatientswithacutecoronarysyndromeandtype2diabetesmellitusaretrospectivestudy |